Respiratory Pharmacology
Respiratory pharmacological medicine primarily deals with agents accustomed to treating the “pathological triad” of respiratory organ sickness. The pathological triad consists of spasm, airway inflammation, and preserved secretions. Agents accustomed treat these conditions accommodates bronchodilators, anti-muscarinic, corticosteroids, mucokinetics, mucolytic, and decongestants, among others. Further reagents utilized in the treatment of respiratory organ sickness square measure gas, antibiotics, native anaesthetics’, metabolism stimulants, and muscle relaxers. All of those, with the exception of gas, square measure mentioned during this paper. explicit stress is placed on medications delivered in Associate in Nursing aerosol kind.
Related Conference of Respiratory Pharmacology
4th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
Respiratory Pharmacology Conference Speakers
Recommended Sessions
- Asthma and Allergy
- Breathing Disorders
- Bronchoscopic Techique
- Cardiopulmonary Sciences
- Chest pain Physical Therapy
- Chronic Obstructive Pulmonary Disease
- Lung Cancer and Treatment
- Lung Infection and Treatment
- Lung transplantation
- Lung transplantation
- Pneumonia
- Pulmonary Cancer
- Pulmonary Critical Care
- Pulmonary diseases-Treatment and therapies
- Pulmonary Parenchyma
- Respiratory Pharmacology
- Respiratory Tract Infections
- Tuberculosis
Related Journals
Are you interested in
- Advancements in Pulmonary Diagnostics - Respiratory 2024 (France)
- Asthma - Tuberculosis-2024 (France)
- Atelectasis and Pneumothorax - Tuberculosis-2024 (France)
- Cardio Pulmonary Disorders - Respiratory 2024 (France)
- Cardiopulmonary Disease - Tuberculosis-2024 (France)
- Chronic Obstructive Pulmonary Disease - Respiratory 2024 (France)
- Chronic Obstructive Pulmonary Disease (COPD) - Tuberculosis-2024 (France)
- Climate Change and Respiratory Diseases - Tuberculosis-2024 (France)
- COVID-19 and Asthma - Respiratory 2024 (France)
- COVID-19 and Respiratory System - Respiratory 2024 (France)
- Epidemiology of TB Disease - Tuberculosis-2024 (France)
- Gastroesophageal reflux disease (GERD) - Tuberculosis-2024 (France)
- Idiopathic Pulmonary Fibrosis - Respiratory 2024 (France)
- Interstitial Lung Disease - Respiratory 2024 (France)
- Latent TB Infection and Active TB Disease - Tuberculosis-2024 (France)
- Lung Cancer - Respiratory 2024 (France)
- Lung Cancer: Screening, Diagnosis & Treatment - Tuberculosis-2024 (France)
- Lung Function in Men with and without HIV - Tuberculosis-2024 (France)
- Lung Infection - Tuberculosis-2024 (France)
- Lung Transplantation - Respiratory 2024 (France)
- Multidrug-resistant TB - Tuberculosis-2024 (France)
- Mycobacterial Infections - Tuberculosis-2024 (France)
- Obstructive Sleep Apnea - Respiratory 2024 (France)
- Occupational Lung Diseases - Respiratory 2024 (France)
- Palliative Care for Advanced Lung Cancer - Tuberculosis-2024 (France)
- Pneumonia - Respiratory 2024 (France)
- Pulmonary Complications of Endocrine Diseases - Tuberculosis-2024 (France)
- Pulmonary Diseases and Therapeutics - Tuberculosis-2024 (France)
- Pulmonary diseases: Treatment, Diagnosis and therapies - Respiratory 2024 (France)
- Pulmonary Edema - Tuberculosis-2024 (France)
- Pulmonary Hypertension - Respiratory 2024 (France)
- Pulmonary Rehabilitation - Respiratory 2024 (France)
- TB Clinical Trials - Tuberculosis-2024 (France)
- TB Diagnosis, Prevention & Treatment - Tuberculosis-2024 (France)
- TB Vaccines - Tuberculosis-2024 (France)
- TB-HIV Co-infections - Tuberculosis-2024 (France)
- Tuberculosis - Respiratory 2024 (France)
- Zoonotic TB - Tuberculosis-2024 (France)